title: Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats.
abstract: The major constituents of isoflavones, daidzein (DZ) and genistein (GE) are known to interact with the alpha and beta estrogen receptors (ERalpha/beta) in several tissues including mammary. In this study, we used ovariectomy (OVX) to model menopause and determined the effects of DZ, GE or 17beta-estradiol (E2) exposures on chemically induced mutagenesis and carcinogenesis in the mammary glands of female Big Blue (BB) transgenic rats. The rats were fed control diet containing the isoflavones and E2 and treated with a single oral dose of 7,12-dimethylbenz[a]anthracene (DMBA) at PND 50. Animals were sacrificed at 16 or 20 weeks post-carcinogen treatment to assess mutant frequencies (MFs) and histopathological parameters, respectively. The isoflavones or E2 supplementation alone resulted in modest increases in the lacI MF that were not significantly different from the MFs measured in rats fed the control diet alone. DMBA exposure, however, induced significant increases in the lacI MFs in the mammary of both OVX and ovary intact (INT) rats and Hprt MFs in spleen lymphocytes (P<or=0.01). In general, feeding the isoflavones or E2 separately did not cause any significant changes in DMBA-induced mutagenicity in the mammary. However, feeding the isoflavone mixture (DZG) resulted in a significant reduction in the DMBA-induced lacI MFs (P<or=0.05). Cell proliferation as measured by PCNA immunohistochemistry was increased in both OVX and INT rats exposed to DMBA as compared with rats fed control diet (P<or=0.05). Mammary histology indicated that hyperplasia was induced in most of the treatment groups including control. Although DMBA treatment did not induce mammary tumors in the OVX rats, adenoma and adenocarcinoma were detected in the mammary glands of INT rats.
authors.affiliation: Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, U.S. FDA Jefferson Laboratories, Jefferson, AR 72079, USA. mmanjanatha@nctr.fda.gov
authors.forename: Mugimane G
authors.initials: MG
authors.lastname: Manjanatha
authors.forename: Sharon
authors.initials: S
authors.lastname: Shelton
authors.forename: Michelle E
authors.initials: ME
authors.lastname: Bishop
authors.forename: Lascelles E
authors.initials: LE
authors.lastname: Lyn-Cook
authors.forename: Anane
authors.initials: A
authors.lastname: Aidoo
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000818:Animals; D030801:Animals, Genetically Modified; D005260:Female; D019833:Genistein / Q000494:pharmacology*; D007529:Isoflavones / Q000494:pharmacology*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced* / Q000517:prevention & control*; D016296:Mutagenesis; D010052:Ovariectomy; D048789:Phytoestrogens / Q000494:pharmacology; D051381:Rats; D013025:Glycine max
chemical_list: D007529:Isoflavones; D048789:Phytoestrogens; D015127:9,10-Dimethyl-1,2-benzanthracene; C004742:daidzein; D019833:Genistein